Applied Clinical Trials Digital Edition - October 2012

Article

Applied Clinical Trials

Applied Clinical TrialsApplied Clinical Trials-10-01-2012
Volume 21
Issue 10

CRO/SPONSOR : Outsourcing to China REGULATORY : Warning Letter Analysis CRO/SPONSOR : Customer Expectation Management Also in this issue : EU Pediatric Regulation, Healthcare Data Informs Research, Modeling and Simulation

Articles in this issue
Applied Clinical Trials Digital Edition - October 2012
i4-792935-1408599365728.jpg
Business and News Update October 2012
i1-792943-1408599343792.jpg
Virtual Trials Come Under Growing Scrutiny
i1-792933-1408599371091.jpg
EDC Autoquery Rate - A Marker for Site Quality
i4-792938-1408599356189.jpg
Warning Letter Study
Diagnostics Needed for Personalized Medicine
i1-792942-1408599346020.jpg
Research, Practice, and Learning
The Local Touch
i4-792946-1408599337099.jpg
Managing Customer Expectations
i1-792991-1408599276308.jpg
Act Cover
i1-792945-1408599340148.jpg
Site-Cost Line Item Charges on the Rise
Richard_Gliklich_132-792940-1408599351663.jpg
Injury Surveillance System Kickoff
i1-792990-1408599277437.jpg
Act Insert Cover
i1-792947-1408599334414.jpg
Outsourcing: China Takes Center Stage
Hidden Successes of Oncology Trial Terminations
Recent Videos
Related Content
Credit: Sebastian Kaulitzki | stock.adobe.com

FDA Grants Accelerated Approval to AbbVie’s Emrelis for the Treatment of NSCLC Based on Phase II Trial Results

Andy Studna, Senior Editor
May 15th 2025
Article

In the Phase II LUMINOSITY study, Emrelis (telisotuzumab vedotin-tllv), a first-in-class c-Met-directed antibody-drug conjugate, demonstrated an overall response rate of 35%.

Unifying Industry to Better Understand GCP Guidance

Unifying Industry to Better Understand GCP Guidance

Andy Studna, Senior Editor
May 7th 2025
Podcast

In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.

Credit: Juan Gärtner | stock.adobe.com

iTeos and GSK Halt TIGIT Antibody Belrestotug Development After Phase II Trials Miss Efficacy Marks in NSCLC and HNSCC

Davy James
May 14th 2025
Article

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end development of the TIGIT-targeting antibody and halt enrollment in all ongoing belrestotug studies.

Site Logo

Unlock Commercial Growth through Data-Driven Patient and HCP Insights Podcast

May 2nd 2025
Podcast
© photon_photo - © photon_photo - stock.adobe.com

Novo Nordisk’s Sogroya Demonstrates Favorable Outcomes in Phase III Trial for Children’s Growth Disorders

Andy Studna, Senior Editor
May 13th 2025
Article

The REAL8 basket study showed Sogroya (somapacitan) was non-inferior to Norditropin (somatropin) in improving yearly growth rate.

Credit: David A Litman | stock.adobe.com

APHINITY Trial Shows Perjeta-Based Regimen Improves 10-Year Overall Survival in HER2-Positive Early Breast Cancer

Davy James
May 13th 2025
Article

Final overall survival results from the Phase III APHINITY trial show a 17% reduction in the risk of death at 10 years for patients with HER2-positive early-stage breast cancer treated with a Perjeta-based adjuvant regimen.

© 2025 MJH Life Sciences

All rights reserved.